Morepen Labs net profit leaps over two-fold to Rs 19.36 crore in Q1
API sales revenue during the quarter grew by 44 percent to Rs 162.06 crore, the filing said.;
Advertisement
New Delhi: Drug firm Morepen Laboratories on Monday reported over two-fold jump in its consolidated net profit at Rs 19.36 crore for the quarter ended June 30, 2020, mainly on account of robust sales in the active pharmaceutical ingredient (API) segment. The company had posted a net profit of Rs 7.65 crore in the corresponding period of the previous fiscal, Morepen Laboratories said in a filing to the BSE.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.